myocardial injury after chemotherapy in treatment of breast cancer
Conditions
Interventions
treatment:tongmai yangxin pills
Control:Placebo
Sponsors
the first affiliated hospital of Henan college of traditional Chinese medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: patients with primary invasive ductal breast cancer verified by cytology or pathology receiving chemotherapy, aged 18-65 years, KPS score 60 points, and expected survival more than 3 months, voluntarily sign informed constent.
Exclusion criteria
Exclusion criteria: patients with systemic metastasis of breast cancerreceiving palliative chemotherapy,with structural heart disease before chemotherapy, with serious disease of vital organs such as heart, liver, kidney, hematopoietic system and systematic severe primary diseases (1.5 times the ALT, AST >upper limit of normal, Cr>ULN), WBC <4*10^9/L, platelets <80*10^9/L, hemoglobin <80g/L. with neurological and psychiatric disorders and unable or unwilling to co-collaborators. Allegy to study drugs,pregnancy, lactation or recent fertility planner. patients participated in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| myocardial enzyme; | — |
Secondary
| Measure | Time frame |
|---|---|
| ultrasonic cardiogram;classification of heart function;ECG, Holter;quality of life;symptoms and signs;6 minutes walk test; | — |
Countries
China
Contacts
Public ContactZhu Mingjun
Outcome results
None listed